dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Medical Research Homepage

Harmonization of resting-state functional MR data across multiple imaging sites

NIH and major radiology societies release findings on accelerating advances in AI for medical imaging

NRG Oncology awarded NCI funding for next six years, receives 'exceptional' score

Study compares colonoscopy polyp detection rates and endoscopist characteristics

MR elastography can measure brain function in milliseconds

Additional routine ultrasounds benefit mothers and babies and could be cost-saving

'Magic mouthwash' effective treatment for mouth sore pain caused by radiation therapy

Leading vascular surgeon presents comparative data analysis on EndoAVF procedures at Society of Interventional Radiology 2019

California Protons Cancer Therapy Center invites patients to enroll in breast cancer study and clinical trial

ACP releases survey results about telehealth technology availability and use among internists

Celsion highlights potentially curative approach to treatment of primary liver cancer

Press releases may be edited for formatting or style
LAWRENCEVILLE, NJ, 21 June 2016 – Celsion Corporation (NASDAQ:CLSN) today announced publication of the article, "RFA plus lyso-thermosensitive liposomal doxorubicin: In search of the optimal approach to cure intermediate-size hepatocellular carcinoma," in Hepatic Oncology, a peer-reviewed medical journal. The article provides a comprehensive overview of the clinical evaluation conducted to date of lyso-thermosensitive liposomal doxorubicin (LTLD), Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of primary liver cancer, also known as hepatocellular carcinoma or HCC. The article details learnings from the Company's 701 patient HEAT Study, a computational modeling study, an experimental animal study and the HEAT Study post hoc subgroup analysis, all of which are consistent with each other and which -- when examined together -- suggest a clearer understanding of a key LTLD heat-based mechanism of action: the longer the target tissue is heated, the greater the doxorubicin tissue concentration. Additionally, the article explores a new hypothesis prompted by these findings: LTLD, when used in combination with Radio Frequency Ablation (RFA) standardized to a minimum dwell time of 45 minutes (sRFA > 45 min), may increase the overall survival (OS) of patients with HCC. Written by Riccardo Lencioni, MD and Dania Cioni, MD of the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine in Miami, Florida, the article is published in the June 10, 2016 issue of the journal, Hepatic Oncology.

"There is an urgent need for new and better treatment options for HCC, the sixth most common cancer in the world, and the third most common cause of death from malignant disease," noted Michael H. Tardugno, Celsion's chairman, president and chief executive officer, in response to the article's publication. "We believe strongly that ThermoDox® may be an important new approach to the treatment of HCC. We are also now committed to learning more about how an LTLD regimen may prolong the survival of patients suffering from this extremely deadly cancer," Mr. Tardugno added.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



Interest in ThermoDox® as a potential treatment option for HCC increased markedly among liver cancer experts worldwide following the announcement by Celsion in July 2015 of the latest OS analysis of the HEAT Study post hoc subgroup. According to this announcement, this most current OS analysis demonstrated that in a large, well bounded, subgroup of patients (n=285 patients, 41% of the previous 701 patient HEAT Study), treatment with a combination of ThermoDox® and standardized RFA (defined as Radio Frequency Ablation standardized to a minimum of 45 minutes or sRFA > 45 min) provided an average 58% improvement in OS compared to standardized RFA alone. The Hazard Ratio (HR) at this analysis is 0.63 (95% CI 0.43 - 0.93) with a p-value of 0.0198. In this large subgroup, median OS for the ThermoDox® plus standardized RFA group translates into a 25.4 month (more than 2.1 year) survival benefit over the standardized RFA only group - totaling approximately 80 months (6-1/2 years, which is considered a curative treatment for HCC) for the ThermoDox® plus standardized RFA group versus 53.6 months for the standardized RFA only group.
  Pages: 1 - 2 - 3 - 4 >>

Medical Research Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED